Why invest in Medicortex Finland Plc?
TBI is the leading cause of central nervous system impairment and there is no reliable way to detect mild injuries - yet! Here's why Medicortex could solve the problem:
- The company’s biggest strength is in the proprietary idea
itself. As per the company’s assessment it is innovative and something that
does not exist at the moment, providing a competitive advantage.
test – detecting a biomarker in a non-invasive sample (urine or saliva) – will address a TBI point of care (POC) diagnostics market that is estimated to exceed €2
new biomarker and the technology surrounding it has been protected by
several patent applications. Some patents have already been granted.
- The company has comprehended that there is a huge need for new innovative and efficient diagnostic tools.
company’s management has noted that the brain injury diagnostics market is
large and the potential customer base vast.
- Medicortex has received several awards and recognitions for its
innovation, as well as research funding from major funders, such as the
US Department of Defense’s medical research funds showing that Medicortex has gained much
Investments will be used primarily for development of the diagnostic kit.
- Basic development including preclinical trial and proof-of-concept human testing has been done.
company has completed two clinical trials where the biomarker was
discovered. The first study included 24 subjects whereas the second
contained 69. The recruitments were carried out in three Finnish
hospitals: Tyks, Satakunta Central Hospital, Vaasa Central Hospital.
- Currently, the third clinical trial to validate the biomarker
in children who have suffered a concussion is underway. The sample collection from
28 TBI and 30 healthy subjects is completed, and the samples are
currently being analyzed for the presence of the biomarker.
Investments always carry risks - Invest responsibly
Note. This information regarding this share issue is not allowed to be published or distributed,
directly or indirectly, in the United States, Australia, Canada, Hong Kong, South Africa, Singapore,
New Zealand, Japan or any other country in which the publication or distribution would be unlawful.
Go back to Investors page